Status:
COMPLETED
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
Lead Sponsor:
National Human Genome Research Institute (NHGRI)
Conditions:
Severe Combined Immunodeficiency
Eligibility:
All Genders
Brief Summary
This study will monitor the long-term effects of gene therapy in patients with severe combined immunodeficiency disease (SCID) due to a deficiency in an enzyme called adenosine deaminase (ADA). It wil...
Detailed Description
The primary purpose of this study is to continue to provide clinical follow-up for ADA-deficient patients treated with gene therapy under the original protocol 90-HG-0195 (IND 3624) and its amendments...
Eligibility Criteria
New patients will not be treated under protocol 90-HG-0195 as new and improved vectors and technologies have become available in the recent years.
New patients with ADA deficiency, however, may be enrolled in protocol 90-HG-0195 for clinical evaluation of their immune system and pre-treatment testing of transduction procedures.
Key Trial Info
Start Date :
September 1 1990
Trial Type :
OBSERVATIONAL
End Date :
July 1 2002
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00001255
Start Date
September 1 1990
End Date
July 1 2002
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Human Genome Research Institute (NHGRI)
Bethesda, Maryland, United States, 20892